Expert Opinion on Drug Delivery
Brief Name:
EXPERT OPIN DRUG DEL
Impact factor:
5 (2023)
ISSN:
1742-5247
Home Page:
Open Access:
No
Publisher:
Taylor and Francis Ltd.
Publication Frequency:
Bimonthly
Publication Start Year:
2004
Annual Articles:
103
Self-citation Rate:
4%
Chinese Academy of Sciences SCI Journal Classification:
| Major category | Ｍinor category | TOP journal | Ｒeview journal |
|---|---|---|---|
Q2 MEDICAL |
PHARMACEUTICALLY | No | Yes |
Subject Classification:
PHARMACOLOGY & PHARMACY
CiteScore:
| CiteScore | SJR | SNIP | CiteScore ranking | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 11.1 | 1.009 | 1.09 |
|
H-Index:
88
SCI Index Status:
Science Citation Index Expanded
Official Review Time:
8 days avg. from submission to first decision
35 days avg. from submission to first post-review decision
9 days avg. from acceptance to online publication
PubMed Central:
Submission Site:
Aims and Scope:
Expert Opinion on Drug Delivery (1742-5247; 1744-7593) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles in drug delivery.
Articles cover all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The journal welcomes:
Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders
Technology evaluations reviewing a particular drug delivery technology
Original research contributions are welcomed in the form of:
- Delivery technologies, vehicles, formulations and devices;
- The delivery of specific drugs and therapeutic classes;
- Modes of entry into the body and applications in certain diseases and disorders.
Editorials commenting on the various drug delivery strategies which have been, and are being, explored
Guidelines on the application of specific drug delivery systems, or in specific disease indications.
The audience for the journal consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Publish in 3 weeks from submission with Accelerated Publication.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Delivery, part of the Expert Collection brand.
Articles cover all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The journal welcomes:
Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders
Technology evaluations reviewing a particular drug delivery technology
Original research contributions are welcomed in the form of:
- Delivery technologies, vehicles, formulations and devices;
- The delivery of specific drugs and therapeutic classes;
- Modes of entry into the body and applications in certain diseases and disorders.
Editorials commenting on the various drug delivery strategies which have been, and are being, explored
Guidelines on the application of specific drug delivery systems, or in specific disease indications.
The audience for the journal consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.
Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;
Article Highlights – an executive summary of the author’s most critical points.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Publish in 3 weeks from submission with Accelerated Publication.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Delivery, part of the Expert Collection brand.
Submission Guidelines:
Disclaimer:
This page displays information about journals or magazines for reference and study purposes only. It is not the official website of any journal or magazine and does not involve publishing matters. Users must verify any publishing-related inquiries directly with the publisher.
If there are any issues with the content displayed on this page, please contact us at: [email protected], and we will verify and address the matter diligently.
This page displays information about journals or magazines for reference and study purposes only. It is not the official website of any journal or magazine and does not involve publishing matters. Users must verify any publishing-related inquiries directly with the publisher.
If there are any issues with the content displayed on this page, please contact us at: [email protected], and we will verify and address the matter diligently.